Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol (Q46161375)

20 December 2017

title

Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol (English)

1 reference

20 December 2017

0 references

Lainas TG

1

1 reference

20 December 2017

Sfontouris IA

2

1 reference

20 December 2017

Zorzovilis IZ

3

1 reference

20 December 2017

Petsas GK

4

1 reference

20 December 2017

Lainas GT

5

1 reference

20 December 2017

Iliadis GS

6

1 reference

20 December 2017

Kolibianakis EM

7

1 reference

20 December 2017

publication date

1 January 2009

1 reference

20 December 2017

Reproductive BioMedicine Online

published in

1 reference

20 December 2017

volume

18

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

15-20

1 reference

20 December 2017

The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Severe OHSS: An 'epidemic' of severe OHSS: a price we have to pay?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Prospective evaluation of endometrial thickness as a predictor of pituitary down-regulation after gonadotropin-releasing hormone analogue administration in an in vitro fertilization program.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Comparison of vitrification and conventional cryopreservation of day 5 and day 6 blastocysts during clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

High pregnancy rates can be achieved after freezing and thawing human blastocysts.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960419-1

7 January 2021

10.1016/S1472-6483(10)60419-1

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19146764

1 reference

20 December 2017